Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue 6, 2006, Pages 263-268

  Carelli, Guareide ^a   Maffei, Francisco H A ^a   Mattar, Luci ^a   Ferrari, Iracema C ^a   Thomazini Santos, Izolete A ^a   De Carvalho, Lídia R ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Experimental thrombosis; Low molecular weight heparin; Rat vena cava

Indexed keywords

ENOXAPARIN; HEPARIN; LIQUEMINE; LOW MOLECULAR WEIGHT HEPARIN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CAVA VEIN; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBIN TIME; THROMBOGENESIS; THROMBOPLASTIN TIME; THROMBUS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; PARTIAL THROMBOPLASTIN TIME; RATS; RATS, WISTAR; THROMBIN TIME; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 33745075993     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093105     Document Type: Article

References (29)

1. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Söderströ G: Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979;15:531-541.
2. Hirsh J, Fuster V: Guide to anticoagulant therapy. 1. Heparin. Circulation 1994;89:1449-1468.
3. Harenberg J: Pharmacology of low molecular weight heparins. Semin Thromb Hemost 1990;16(suppl):2-8.
4. Weitz JI: Low molecular weight heparins. N Engl J Med 1997;337:688-698.
5. Holmer E, Söderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis 1986;16(suppl 2):1-7.
6. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fed S, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG: Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999;81:589-593.
7. Sandset P, Abildgaard U, Larsen M: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
8. Bara L, Bloch M, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J: Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993;69:443-452.
9. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F: Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16(suppl 2):30-37.
10. Andrassy K, Eschenfelder V: Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996;81(suppl 2):29-38.
11. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
12. Perez-Requejo JL, Solano OL, Garcia MP, Santarelli MT: Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin). Thromb Res 1997;85:259-265.
13. Altman R, Scazziota A, Rouvier J: Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor (TFPI). Thromb Haemost 1999;(suppl):195.
14. Reyers I, Mussoni L, Donati MB, Gaetano G: Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980;18:669-674.
15. Carvalho I, Thomazine IA, Maffei FHA, Curi PR, Mattar L: Trombose venosa experimental por ligadura de veia cava no rato: comparação entre diferentes técnicas. 7. Reunião anual da Federação de Sociedades de Biologia Experimental, Caxambu. Anais 1992, p 69.
16. Lavelle SM, MacIomhair M: Bleeding times and the antithrombotic effects of high-dose aspirin and heparin in rats. Ir J Med Sci 1998;167:216-220.
17. Stella L, Donatti MB, Gaetano G: Bleeding time in laboratory animals. 1. Aspirin does not prolong bleeding time in rats. Thromb Haemost 1975;7:709-716.
18. Palm M, Mattsson C, Svahn CM, Weber M: Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Thromb Haemost 1990;64:127-132.
19. Dejana E, Callioni A, Quintana A, Gaetano G: Bleeding time in laboratory animals. 2. A comparison of different assay conditions in rats. Thromb Res 1979;15:191-197.
20. Curi PR, Moraes RV: Associação, homogeneidade e contrastes entre proporções em tabelas contendo distribuições multinomiais. Ciência e Cultura 1981;33:712-722.
21. Fisher LD, Van Belle G: Biostatistics: A Methodology for the Health Sciences. New York, Wiley, 1993, p 991.
22. Young E, Wells P, Holloway S, Weitz J, Hirsh J: Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-304.
23. Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR: The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haematol 1985;60:695-704.
24. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999;19:2251-2262.
25. Hiebert LM, Wice SM, Ping T, Herr D, Laux V: Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route. Thromb Haemost 2001;85:114-118.
26. Miyake Y, Yokota K, Fujishima Y, Sukamoto T: The effects of danaparoid, dalteparin, and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. Blood Coagul Fibrinolysis 2001;12:349-357.
27. Mischke R, Nimmerfall K: Effect of a high single subcutaneous dose of unfractionated heparin on platelet function in dogs. Berl Munch Tierärztl Wochenschr 2000;113:60-64.
28. Katsuura Y, Tanabe H, Kiyoshi M, Funatsu A: Comparison of hemorrhagic effect of heparin and human activated protein C with use of Thrombostat 4000. Haemostasis 1996;26:203-209.
29. Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P: Low molecular weight heparins prevent thrombin-induced thromboembolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Haematologica 2001;86:297-302.